Stéphanie Malaquin

Dr. Stéphanie Malaquin


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in Critical Care
Verified
Journal Article
Open access
PDF file
FTFabrice Thiolliere
Fabrice Thiolliere
CFClaire Falandry
Claire Falandry
Bernard AllaouchicheBernard Allaouchiche
Bernard Allaouchiche
VGVictor Geoffray
Victor Geoffray
LBLaurent Bitker
Laurent Bitker
CVCharles-Hervé Vacheron
Charles-Hervé Vacheron
Objective: To compare old patients hospitalized in ICU for respiratory distress due to COVID-19 with old patients hospitalized in ICU for a non-COVID-19-related reason in terms of autonomy and quality of life. Design: Comparison of two prospective multi-centric studies. Setting: This study was based on two prospective multi-centric studies, the Senior-COVID-Rea cohort (COVID-19-diagnosed ICU-admitted patients aged over 60) and the FRAGIREA cohort (ICU-admitted patients aged over 70). Patients: We included herein the patients from both cohorts who had been evaluated at day 180 after admission (ADL score and quality of life). Interventions: None. Measurements and main results: A total of 93 COVID-19 patients and 185 control-ICU patients were included. Both groups were not balanced on age, body mass index, mechanical ventilation, length of ICU stay, and ADL and SAPS II scores. We modeled with ordered logistic regression the influence of COVID-19 on the quality of life and the ADL score. After adjustment on these factors, we observed COVID-19 patients were less likely to have a loss of usual activities (aOR [95% CI] 0.47 [0.23; 0.94]), a loss of mobility (aOR [95% CI] 0.30 [0.14; 0.63]), and a loss of ADL score (aOR [95% CI] 0.30 [0.14; 0.63]). On day 180, 52 (56%) COVID-19 patients presented signs of dyspnea, 37 (40%) still used analgesics, 17 (18%) used anxiolytics, and 14 (13%) used antidepressant. Conclusions: COVID-19-related ICU stay was not associated with a lower quality of life or lower autonomy compared to non-COVID-19-related ICU stay.

1 August 2017 in Anaesthesia Critical Care & Pain Medicine
Verified
Journal Article
Closed access
SMStéphanie Malaquin
Stéphanie Malaquin
YMYazine Mahjoub
Yazine Mahjoub
AMArianna Musi
Arianna Musi
EZElie Zogheib
Elie Zogheib
ASAlexis Salomon
Alexis Salomon
HDHerve Dupont
Herve Dupont

1 July 2016 in Medicine
Verified
Journal Article
Open access
SMStéphanie Malaquin
Stéphanie Malaquin
LRLionel Rebibo
Lionel Rebibo
CCCyril Chivot
Cyril Chivot
LBLouise Badoux
Louise Badoux
YMYazine Mahjoub
Yazine Mahjoub
HDHerve Dupont
Herve Dupont
Afibrinogenemia is a rare coagulation disorder. Clinical features of spontaneous bleeding, bleeding after minor trauma, or after surgery have been described as well as thrombo-embolic complications. In this article, we presented the case of a 19-year old female with congenital afibrinogenemia who was admitted with a spontaneous intrahepatic hematoma. Supportive treatment including transfusion and fibrinogen administration, associated with repeated packing surgeries and selective embolization, were successfully performed.

11 July 2016 in Toxins
Verified
Journal Article
Open access
PDF file
SMStéphanie Malaquin
Stéphanie Malaquin
SBSam BAYAT
Sam BAYAT
OAOsama Abou-Arab
Osama Abou-Arab
GMGilles Mourier
Gilles Mourier
ELEmmanuel Lorne
Emmanuel Lorne
YMYazine Mahjoub
Yazine Mahjoub
Sarafotoxins (SRTX) are endothelin-like peptides extracted from the venom of snakes belonging to the Atractaspididae family. A recent in vivo study on anesthetized and ventilated animals showed that sarafotoxin-b (SRTX-b), extracted from the venom of Atractaspis engaddensis, decreases cardiac output by inducing left ventricular dysfunction while sarafotoxin-m (SRTX-m), extracted from the venom of Atractaspis microlepidota microlepidota, induces right ventricular dysfunction with increased airway pressure. The aim of the present experimental study was to compare the respiratory effects of SRTX-m and SRTX-b. Male Wistar rats were anesthetized, tracheotomized and mechanically ventilated. They received either a 1 LD50 IV bolus of SRTX-b (n = 5) or 1 LD50 of SRTX-m (n = 5). The low-frequency forced oscillation technique was used to measure respiratory impedance. Airway resistance (Raw), parenchymal damping (G) and elastance (H) were determined from impedance data, before and 5 min after SRTX injection. SRTX-m and SRTX-b injections induced acute hypoxia and metabolic acidosis with an increased anion gap. Both toxins markedly increased Raw, G and H, but with a much greater effect of SRTX-b on H, which may have been due to pulmonary edema in addition to bronchoconstriction. Therefore, despite their structural analogy, these two toxins exert different effects on respiratory function. These results emphasize the role of the C-terminal extension in the in vivo effect of these toxins.

6 May 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
HDHerve Dupont
Herve Dupont
SMStéphanie Malaquin
Stéphanie Malaquin
LVLéonie Villeret
Léonie Villeret
PMPierre-Yves Macq
Pierre-Yves Macq
NANacim Ammenouche
Nacim Ammenouche
CTchouaki Taieb
chouaki Taieb
The usefulness of (1,3)-ß-d-glucan (BDG) detection for the diagnosis of intra-abdominal candidiasis and treatment monitoring is unknown. A prospective, single-center study of consecutive patients admitted to an ICU with complicated intra-abdominal infection (IAI) over a 2-year period was conducted. BDG was measured in the peritoneal fluid and serum between day 1 (D1) and D10. Patients with a positive peritoneal fluid yeast culture (YP) were compared to those with a negative yeast culture (YN). The evolution of serum BDG was compared in the two groups. Seventy patients were included (sixty-five analyzed): YP group (n = 19) and YN group (n = 46). Median peritoneal BDG concentration during surgery was 2890 pg.mL−1 [IQR: 942–12,326] in the YP group vs. 1202 pg.mL−1 [IQR: 317–4223] in the YN group (p = 0.13). Initial serum BDG concentration was 130 pg.mL−1 [IQR: 55–259] in the YP group vs. 88 pg.mL−1 [IQR: 44–296] in the YN group (p = 0.78). No difference in evolution of serum BDG concentrations was observed between the groups (p = 0.18). In conclusion, neither peritoneal BDG nor serum BDG appear to be good discriminating markers for the diagnosis of yeast IAI. In addition, monitoring the evolution of serum BDG in yeast IAI did not appear to be of any diagnostic value.